Midodrine is named as an intervention in 3 current clinical trials in our Canada and India registers. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Institute of Liver and Biliary Sciences, India (1). The most-studied condition is Acute on Chronic Liver Failure.
Midodrine was first approved in the US on 6 Sep 1996.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)
NCT05058612 · ClinicalTrials.gov ↗ · Vasoplegia
|
Phase 4 | Recruiting | University of Alberta | Canada |
|
Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension
NCT06405555 · ClinicalTrials.gov ↗ · Heart Failure With Reduced Ejection Fraction, Hypotension, LV Dysfunction
|
Phase 2/3 | Recruiting | Ottawa Heart Institute Research Corporation | Canada |
|
Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.
NCT07422948 · ClinicalTrials.gov ↗ · Acute on Chronic Liver Failure
|
Not applicable | Not yet open | Institute of Liver and Biliary Sciences, India | India |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
11 single-substance products containing Midodrine on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Institute of Liver and Biliary Sciences, India | 1 |
| Ottawa Heart Institute Research Corporation | 1 |
| University of Alberta | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 2 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada and India registers name Midodrine as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Institute of Liver and Biliary Sciences, India (1), Ottawa Heart Institute Research Corporation (1) and University of Alberta (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 11 single-substance products containing Midodrine, for example Midon 2.5 mg tablets (CHEPLAPHARM Arzneimittel GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 1 entry for Midodrine: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Midodrine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Midodrine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Midodrine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.